About Alexis Bio
Alexis Bio is a Healthcare company based in Boston (United States) founded in 2016 by Jon Adkins, Krysta Moulton, and Paul Holzer. Cell therapies for common and rare diseases are developed. Alexis Bio has raised $1.33 million across 1 funding round. The company has 3 employees. Alexis Bio has completed 2 acquisitions, including ESSA Pharma and Repare Therapeutics. Its chief executive, as recorded, is Paul Holzer. Alexis Bio offers products and services including Genetically Optimized Cells and Donor Tissues and Organs. Its focus areas include Life Sciences, Rare Diseases, Drugs and Diversified. Its legal entity is XENOTHERAPEUTICS INC. Its competitors include Moderna, BridgeBio and Spark Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Alexis Bio was founded in 2016 and is based in Boston, United States. Multipotent stem cell-based therapies are developed by the company for neurodegenerative diseases, infectious diseases, and skin and wound care. Lead candidates include Xeno-Skin, a live biotherapeutic skin xenotransplant for severe burns, and AB001 for Parkinsons disease. Operations focus on advancing these treatments in the biotechnology sector.
- Headquarters Boston, United States
- Employees 3
- Founders Jon Adkins, Krysta Moulton, Paul Holzer
- SectorsHealthcare
- Phone•••• ••••
- Website alexisbio.com
- Social LinkedIn X Facebook
- Legal Name Xenotherapeutics Inc
- Total Equity Funding$1.33M (USD)
in 1 rounds
- Latest Funding Round$1.33M (USD), Seed
Apr 2021
- Employee Count3
- Investments & AcquisitionsESSA Pharma
& 1 more
Products & Services of Alexis Bio
Alexis Bio offers a comprehensive portfolio of products and services, including Genetically Optimized Cells and Donor Tissues and Organs.
Engineered animal cells to replace human cells for healing and function restoration.
Genetically altered materials for clinical replacement of damaged body parts.
Funding Insights of Alexis Bio
Alexis Bio has successfully raised a total of $1.33M through 1 strategic funding round. The most recent funding activity was a Seed round of $1.33 million completed in April 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.33M
- Total Rounds 1
- Last Round Seed — $1.33M
- First Round $1.33M
(Apr 2021)
All 1 funding rounds of Alexis Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2021 | $1.33M | Seed | – | – | – |
People of Alexis Bio
3 people are tracked at Alexis Bio (3 in leadership); the tracked headcount is 3.
| Name | Role | Group |
|---|---|---|
Jon Adkins | Co-Founder | Leadership |
Krysta Moulton | Co-Founder | Leadership |
Paul Holzer | Co-Founder and CEO | Leadership |
Complete people profiles for Alexis Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Alexis Bio
Alexis Bio has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include ESSA Pharma and Repare Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Targeted cancer therapies for genetic tumor alterations are developed. | reparerx.com | Montreal, Canada | 2016 | Nov 2025 | •••• | |
Small molecule drugs for cancer treatment are developed. | essapharma.com | Vancouver, Canada | 2009 | Jul 2025 | •••• |
Complete acquisition details for Alexis Bio
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Alexis Bio
4 dated milestones of Alexis Bio across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Alexis Bio is founded.
- Funding First funding round of $1.3M.
- Acquisition Acquires ESSA Pharma.
- Acquisition Acquires Repare Therapeutics.
Competitors of Alexis Bio
Alexis Bio has 3 listed competitors in our database, 3 of them funded. They include Moderna, BridgeBio and Spark Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. |
Detailed competitors of Alexis Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Cell Therapy
3 companies that operate in the same segment as Alexis Bio (Cell Therapy) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | 520 | ||
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Alexis Bio
Complete news archive for Alexis Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alexis Bio
Alexis Bio was founded in 2016 and raised its 1st funding round 5 years after it was founded.
Alexis Bio is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Paul Holzer is the CEO of Alexis Bio, as recorded in our data. They have also founded this company.
Alexis Bio is a funded company, having raised a total of $1.33M across 1 funding round to date. The company's 1st funding round was a Seed of $1.33M, raised on Apr 2021.
Alexis Bio has 3 employees.
Alexis Bio was founded in 2016 and is based in Boston, United States. Multipotent stem cell-based therapies are developed by the company for neurodegenerative diseases, infectious diseases, and skin and wound care. Lead candidates include Xeno-Skin, a live biotherapeutic skin xenotransplant for severe burns, and AB001 for Parkinsons disease. Operations focus on advancing these treatments in the biotechnology sector.
Alexis Bio's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Alexis Bio offers Genetically Optimized Cells and Donor Tissues and Organs.
Alexis Bio has made 2 acquisitions, including ESSA Pharma, and Repare Therapeutics.
Alexis Bio operates through Xenotherapeutics Inc.